Structural basis of preexisting immunity to the 2009 H1N1 pandemic influenza virus

Science

Volumn 328, Issue 5976, 2010, Pages 357-360

  Xu, Rui ^a   Ekiert, Damian C ^a   Krause, Jens C ^b   Hai, Rong ^c   Crowe Jr , James E ^b   Wilson, Ian A ^a  

^a SCRIPPS RESEARCH INSTITUTE   (United States)

^b VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ENVELOPE PROTEIN; INFLUENZA VACCINE; NEUTRALIZING ANTIBODY; VIRUS HEMAGGLUTININ;

ANTIBODY; ANTIGEN; BIOCHEMISTRY; CRYSTAL STRUCTURE; DISEASE RESISTANCE; EPIDEMIC; IMMUNITY; INFLUENZA; NEUTRALIZATION; VIRUS;

ANTIGENICITY; ARTICLE; BINDING SITE; CONFORMATION; CROSS REACTION; CRYSTAL STRUCTURE; GLYCOSYLATION; IMMUNITY; INFLUENZA VIRUS A H1N1; NONHUMAN; PANDEMIC; PRIORITY JOURNAL; PROTEIN STRUCTURE;

AGE FACTORS; AMINO ACID SEQUENCE; ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; ANTIGENIC VARIATION; CROSS REACTIONS; CRYSTALLOGRAPHY, X-RAY; DISEASE OUTBREAKS; EPITOPES; GLYCOSYLATION; HEMAGGLUTININ GLYCOPROTEINS, INFLUENZA VIRUS; HEMAGGLUTININS, VIRAL; HUMANS; IMMUNOGLOBULIN FAB FRAGMENTS; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA VACCINES; INFLUENZA, HUMAN; MODELS, MOLECULAR; MOLECULAR SEQUENCE DATA; PROTEIN CONFORMATION;

ORTHOMYXOVIRIDAE; SUIDAE;

EID: 77951165843     PISSN: 00368075     EISSN: 10959203     Source Type: Journal    
DOI: 10.1126/science.1186430     Document Type: Article

References (39)

1. P. Palese, Nat. Med. 10 (suppl.), S82 (2004).
2. World Health Organization, www.who.int
3. J. J. Skehel, D. C Wiley, Annu. Rev. Biochem. 69, 531 (2000).
4. Most neutralizing antibodies that result from viral infection or vaccination specifically target the HA. The current seasonal flu vaccine formulation includes representative strains from the circulating H1N1, H3N2, and influenza B viruses.
5. G. J. Smith et al., Nature 459, 1122 (2009).
6. R. J. Garten et al., Science 325, 197 (2009); published online 22 May 2009 (10.1126/science.1176225).
7. Three H1 genes from the human lineage are included. They respresent human H1 HAs from the 1918 influenza pandemic (A/South Carolina/1/18) and later seasonal strains (A/Puerto Rico/8/34 and A/Brisbane/59/2007). A/Brisbane/59/2007 is the current seasonal vaccine strain. In the swine lineage, classical swine HAs (A/swine/lowa/15/1930 and A/swine/Ohio/511445/2007) are listed along with swine-origin human viruses (A/New Jersey/1976 and A/California/04/2009).
8. G. J. Smith et al., Proc. Natl. Acad. Sci. U.S.A. 106, 11709 (2009).
9. S. M. Zimmer, D. S. Burke, N. Engl. J. Med. 361, 279 (2009).
10. J. C. Gaydos, F. H. Top Jr., R. A. Hodder, P. K. Russell, Emerg. Infect. Dis. 12, 23 (2006).
11. Materials and methods are available as supporting material on Science Online.
12. T. Lin et al., Virology 392, 73 (2009).
13. S. J. Gamblin et al., Science 303, 1838 (2004); published online 5 February 2004 (10.1126/science.1093155).
14. J. Stevens et al., Science 303, 1866 (2004); published online 5 February 2004 (10.1126/science.1093373).
15. A. J. Caton, G. G. Brownlee, J. W. Yewdell, W. Gerhard, Cell 31, 417 (1982).
16. G. G. Brownlee, E. Fodor, Philos. Trans. R. Soc. London Ser. B 356, 1871 (2001).
17. Residue numbering based on H3 HA, as in I. A. Wilson et al., Nature 289, 366 (1981).
18. The RMSD between the membrane-distal domain of CA04 to other H1 HA structures [as Protein Data Bank identification codes (PDB IDs)] are as follows: 1RD8 (A/South Carolina/1/18, 0.58 Å); IRUZ (A/South Carolina/ 1/18, 0.76 Å); 1RU7 (A/Puerto Rico/8/34, 0.63 Å); 1RUY (A/swine/lowa/15/1930, 0.62 Å); 3HTO (A/wild duck/ Jiangxi/12416/2005, 0.60 Å).
19. In the crystal structures of H1 HA, the three peptide segments composing the Sa site are all anchored at both ends by aromatic residues whose side chains are buried inside the HA1 receptor binding domain. These residues are absolutely conserved in all H1 HAs, and the numbers of residues between these hydrophobic anchors remain the same, thus maintaining the structural integrity of the Sa site. Across different subtypes, however, these aromatic residues are less well conserved, and slight variations in the length of the component peptide segments may occur.
20. Y. Itoh et al., Nature 460, 1021 (2009).
21. A similar situation may presumably have happened before the 1900s, for which we have insufficient data.
22. K. Hancock et al., N. Engl. J. Med. 361, 1945 (2009).
23. Centers for Disease Control and Prevention (CDC), MMWR Morb. Mortal. Wkly. Rep. 58, 521 (2009).
24. J. K. Taubenberger, D. M. Morens, Emerg. Infect. Dis, 12, 15 (2006).
25. Centers for Disease Control and Prevention, www.cdc.gov/h1n1flu/.
26. S. Jain et al. [2009 Pandemic Influenza A (H1N1) Virus Hospitalizations Investigation Team], N. Engl, J. Med. 361, 1935 (2009).
27. S. A. Webb et al. (ANZIC Influenza Investigators), N. Engl. J. Med. 361, 1925 (2009).
28. G. Chowell et al., N. Engl J. Med. 361, 674 (2009).
29. B. Cao et al. [National Influenza A Pandemic (H1N1) 2009 Clinical Investigation Group of China], N. Engl. J. Med. 361, 2507 (2009).
30. D. N. Fisman et al., N. Engl. J. Med. 361, 2000 (2009).
31. I. T. Schulze, J. Infect Dis. 176 (suppl. 1), S24 (1997).
32. Because of limited surveillance during this time period, it is difficult to estimate exactly when most H1 viruses acquired glycosylate sites in the vicinity of Sa. Between 1933 and 1943, some isolates have predicted glycans in the region and others do not, suggesting that variants with and without Sa glycans cocirculated during this time. The last isolate without any predicted glycans in the Sa site was A/Weiss/1943 (Fig. 2F and table 52).
33. X. Yu et al., Nature 455, 532 (2008).
34. J. C. Krause et al., J. Virol. 84, 3127 (2010).
35. Indeed, the electron density is weak in this region and is probably only present at all because of a weak crystal contact to an adjacent HA molecule.
36. Z. Xing, C. J. Cardona, Emerg. Infect. Dis. 15, 1847 (2009).
37. J. A. Greenbaum et al., Proc. Natl. Acad. Sci. U.S.A. 106, 20365 (2009).
38. Single-letter abbreviations for the amino acid residues are as follows: A, Ala; C, Cys; D, Asp; E, Glu; F, Phe; G, Gly; H, His; I, He; K, Lys; L, Leu; M, Met; N, Asn; P, Pro; Q, GIn; R, Arg; S, Ser; T, Thr; V, Val; W, Trp; and Y, Tyr.
39. The work was supported in part by NIH grants AI058113 (I.A.W., J.E.C, and P. Palese) and AI057157 (J.E.C.), predoctoral fellowships from the Achievement Rewards for College Scientists Foundation and the NIH Molecular Evolution Training Program GM080209 (D.C.E.), and the Skaggs Institute for Chemical Biology. X-ray diffraction data sets were collected at the Stanford Synchrotron Radiation Lightsource beamline 9-2 and at the Advanced Photon Source beamline 23ID-B (GM/CA-CAT). The GM/CA CAT 23-ID-B beamline has been funded in whole or in part with federal funds from National Cancer Institute (Y1-CO-1020) and National Institute of General Medical Sciences (Y1-GM-1104). Use of the Advanced Photon Source (APS) was supported by the U.S. Department of Energy, Basic Energy Sciences, Office of Science, under contract no. DE-AC02-06CH11357. We thank P. Palese (Mount Sinai School of Medicine) for providing the CA04 clone and helpful comments, X. Dai and M. A. Elsliger (Scripps Research Institute) and C J. Huffman (Vanderbilt University) for expert technical assistance, H. Tien and D. Marciano of the Robotics Core at the Joint Center for Structural Genomics for automated crystal screening, and M. Becker and the staff of the APS GM/CA CAT 23-ID-B for beamline support. This is publication 20395 from the Scripps Research Institute. Coordinates and structure factors are deposited in the PDB [3LZG for CA04 HA (two trimers) and 3LZF for 1918 HA/2D1 complex]. Vanderbilt University has applied for a provisional patent covering the diagnostic and therapeutic use of antibodies described in this paper. J.E.C. Jr. is a founder of the vaccine company Corbeau Biotech LLC and has consulted for Medlmmune, Novartis, Sanofi, and lmmunobiosciences. J.C.K. is funded by a Pediatric Infectious Diseases Society Fellowship funded by Medlmmune and AstraZeneca.